ICERWATCH PUBLIC COMMENTS
Patients Rising Now Comments on ICER Draft Evidence Report: "Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value"
JAK Inhibitors for Rheumatoid Arthritis: Draft Evidence Report
Patients Rising Now appreciates the opportunity to provide our comments on ICER’s October 11th Draft Evidence Report “Janus Kinase Inhibitors for Rheumatoid Arthritis.”
Patients Rising NOW Comments: ICER 2020 Value Assessment Framework: Proposed Changes
Patients Rising Now is welcomes the opportunity to provide recommendations and comments about the pros and cons of ICER’s August 21st document outlining proposed changes to its Value Assessment Framework’s processes and methodology. As advocates for patients with...
Institute for Patient Access & Affordability Comments on ICER Oral Semaglutide for Type 2 Diabetes: Draft Evidence Report
Institute for Patient Access & Affordability (IPAA) is a new program division of Patients Rising with the mission to provide patient-powered pathways to help both public and private payers as they make critical coverage decisions for patients with rare and chronic...